S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
“The Bull Market Is Officially OVER”  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
“The Bull Market Is Officially OVER”  (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
Reclusive trader scores 20 straight years of winning trades. Learn how (Ad)
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
“The Bull Market Is Officially OVER”  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
“The Bull Market Is Officially OVER”  (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
Reclusive trader scores 20 straight years of winning trades. Learn how (Ad)
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
“The Bull Market Is Officially OVER”  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
“The Bull Market Is Officially OVER”  (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
Reclusive trader scores 20 straight years of winning trades. Learn how (Ad)
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
“The Bull Market Is Officially OVER”  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
“The Bull Market Is Officially OVER”  (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
Reclusive trader scores 20 straight years of winning trades. Learn how (Ad)
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
NASDAQ:BMRN

BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News

$97.12
-1.54 (-1.56%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$97.00
$99.56
50-Day Range
$80.93
$98.66
52-Week Range
$70.73
$100.30
Volume
1.29 million shs
Average Volume
1.24 million shs
Market Capitalization
$18.01 billion
P/E Ratio
231.24
Dividend Yield
N/A
Price Target
$112.50

BioMarin Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
15.8% Upside
$112.50 Price Target
Short Interest
Healthy
5.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.93
Upright™ Environmental Score
News Sentiment
0.19mentions of BioMarin Pharmaceutical in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$1.28 M Sold Last Quarter
Proj. Earnings Growth
173.86%
From $0.88 to $2.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

162nd out of 1,038 stocks

Pharmaceutical Preparations Industry

60th out of 510 stocks

BMRN stock logo

About BioMarin Pharmaceutical (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Stock News Headlines

10 Analysts Have This to Say About Biomarin Pharmaceutical
Why BioMarin Pharmaceuticals Fell 6.9% on Thursday
Recap: Biomarin Pharmaceutical Q3 Earnings
Biomarin Pharmaceutical Inc. Q3 Loss decreases, but misses estimates
See More Headlines
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Company Calendar

Last Earnings
10/26/2022
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BMRN
CUSIP
09061G10
Employees
3,045
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$112.50
High Stock Price Forecast
$135.00
Low Stock Price Forecast
$74.00
Forecasted Upside/Downside
+15.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$-64,080,000.00
Pretax Margin
5.01%

Debt

Sales & Book Value

Annual Sales
$1.85 billion
Cash Flow
$0.87 per share
Book Value
$23.26 per share

Miscellaneous

Free Float
182,228,000
Market Cap
$18.01 billion
Optionable
Optionable
Beta
0.34

Social Links


Key Executives

  • Mr. Jean-Jacques Bienaime M.B.A.Mr. Jean-Jacques Bienaime M.B.A. (Age 69)
    MBA, Chairman & CEO
    Comp: $3.67M
  • Mr. Brian R. MuellerMr. Brian R. Mueller (Age 48)
    Exec. VP of Fin. & CFO
    Comp: $1.13M
  • Dr. C. Greg Guyer Ph.D. (Age 60)
    CTO and Exec. VP of Global Manufacturing & Technical Operations
    Comp: $1.75M
  • Mr. Jeffrey Robert AjerMr. Jeffrey Robert Ajer (Age 60)
    Exec. VP & Chief Commercial Officer
    Comp: $1.2M
  • Dr. Henry J. Fuchs M.D. (Age 64)
    Ph.D., Pres of Worldwide R&D
    Comp: $1.52M
  • Ms. Erin Burkhart
    Group VP & Chief Accounting Officer
  • Traci McCarty
    VP of Investor Relations
  • Mr. George Eric DavisMr. George Eric Davis (Age 51)
    Exec. VP, Gen. Counsel & Sec.
  • Mr. Philip Lo Scalzo
    Sr. VP & Chief Compliance Officer
  • Ms. Humaira Serajuddin
    Sr. VP & Chief Marketing Officer













BMRN Stock - Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BMRN shares.
View BMRN analyst ratings
or view top-rated stocks.

What is BioMarin Pharmaceutical's stock price forecast for 2023?

13 brokerages have issued 1 year price objectives for BioMarin Pharmaceutical's shares. Their BMRN share price forecasts range from $74.00 to $135.00. On average, they anticipate the company's stock price to reach $112.50 in the next year. This suggests a possible upside of 15.8% from the stock's current price.
View analysts price targets for BMRN
or view top-rated stocks among Wall Street analysts.

How have BMRN shares performed in 2022?

BioMarin Pharmaceutical's stock was trading at $88.35 at the beginning of 2022. Since then, BMRN stock has increased by 9.9% and is now trading at $97.12.
View the best growth stocks for 2022 here
.

Are investors shorting BioMarin Pharmaceutical?

BioMarin Pharmaceutical saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 9,820,000 shares, a decline of 12.9% from the October 31st total of 11,270,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the short-interest ratio is currently 7.7 days.
View BioMarin Pharmaceutical's Short Interest
.

When is BioMarin Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our BMRN earnings forecast
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its earnings results on Wednesday, October, 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by $0.41. The biotechnology company had revenue of $505.30 million for the quarter, compared to analyst estimates of $516.03 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 2.50% and a net margin of 4.18%. BioMarin Pharmaceutical's revenue was up 23.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.03) EPS.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical updated its FY 2022 earnings guidance on Wednesday, November, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.06 billion-$2.16 billion, compared to the consensus revenue estimate of $2.12 billion.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (9.50%), Vanguard Group Inc. (9.22%), Barclays PLC (1.21%), Palo Alto Investors LP (1.07%), California Public Employees Retirement System (0.71%) and UBS Asset Management Americas Inc. (0.69%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends
.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $97.12.

How much money does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $18.01 billion and generates $1.85 billion in revenue each year. The biotechnology company earns $-64,080,000.00 in net income (profit) each year or $0.42 on an earnings per share basis.

How many employees does BioMarin Pharmaceutical have?

The company employs 3,045 workers across the globe.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889.

This page (NASDAQ:BMRN) was last updated on 11/30/2022 by MarketBeat.com Staff